Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal

Poudel, Kapil Madi; Shah, Neha; Prakash, Manab; Deo, Santosh Kumar; Bhandari, Sunita; Poudel, Tika Ram

doi:10.1186/s12879-022-07406-2

BMC Infectious Diseases

Table 1 Socio-demographic characteristics and relationship of comorbidities with AEFIs after the first dose

From: Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal

Variables	Category	Frequency/percent of participant	Frequency/percent^a of AEFI with 95% CI	p-value^b
Total participants		602	481[79.9%, (76.7–83.1)]
Gender	Female	183 (30.4%)	157 [85.8%, (80.7–90.8)]	0.023
Gender	Male	419 (69.6%)	324 [77.3%, (73.3–81.3)]	0.023
Age	18–30	222 (36.9%)	192 [86.5%, (82.0–91.0)]	0.001
	31–45	239 (39.7%)	192 [80.3%, (75.3–85.4)]
	46–60	98 (16.3%)	67 [68.4%, (59.2–77.6)]
	≥ 61	43 (7.1%)	30 [69.8%, (56.0–83.5)]
Marital status	Unmarried	148 (24.6%)	129 [87.2%, (81.8–92.5)]	0.016
Marital status	Married	454 (75.4%)	352 [77.5%, (73.7–81.4)]	0.016
Education status	Illiterate	27 (4.5%)	20 [74.1%, (57.5–90.6)]	0.412
	Primary	76 (12.6%)	57 [75%, (65.3–84.7)]
	Secondary	205 (34.0%)	162 [79.0%, (73.4–84.6)]
	University	294 (48.8%)	242 [82.3%, (77.9–86.7)]
Type of occupation	Health worker	140 (23.3%)	122 [87.1%, (81.6–92.7)]	0.001
	Government worker	267 (44.3%)	205 [76.8%, (71.7–81.8)]
	Media worker	23 (3.8%)	12 [52.2%, (31.8–72.6)]
	Others	172 (28.6%)	142 [82.6%, (76.9–88.2)]
Smoking	Yes	36 (5.9%)	25 [69.4%, (54.4–84.5)]	0.162
Smoking	No	566 (94.1%)	456[80.6%, (77.3–83.8)]	0.162
Drinking alcohol	Yes	128 (21.3%)	94[73.4%, (65.8–81.1)]	0.053
Drinking alcohol	No	474 (78.7%)	387 [81.6%, (78.2–85.1)]	0.053
Comorbid illness	Yes	91 (15.1%)	66 [72.5%, (63.4–81.7)]	0.078
Comorbid illness	No	511 (84.9%)	415[81.2%, (77.8–84.6)]	0.078
Prior COVID-19 infection	Yes	28 (4.6%)	22 [78.6%, (63.4–93.8)]	0.999
Prior COVID-19 infection	No	574 (95.4%)	459[80.0%, (76.7–83.2)]	0.999
Prior COVID-19 infection in a family	Yes	32 (5.3%)	28[87.5%, (76.0–98.9)]	0.381
Prior COVID-19 infection in a family	No	570 (94.7%)	453[79.5%, (76.2–82.8)]	0.381
Involvement in treatment of COVID-19 patient	Yes	98 (16.3%)	81 [82.6%, (75.1–90.1)]	0.500
Involvement in treatment of COVID-19 patient	No	504 (83.7%)	400 [79.4%, (75.9–82.9)]	0.500

^aPercentage was calculated for the frequency of the category variable
^bThe chi-square test was used for AEFIs observed with the first dose in each group in the study population

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com